María
Díez Campelo
Profesora Asociada CC. Salud
Universidad de Navarra
Pamplona, EspañaPublicacions en col·laboració amb investigadors/es de Universidad de Navarra (10)
2023
-
Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion
Cancer Medicine, Vol. 12, Núm. 16, pp. 16788-16792
-
Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution
eLife, Vol. 12
2022
-
Prognostic impact of micromegakaryocytes in primary myelodysplastic syndromes
Leukemia and Lymphoma, Vol. 63, Núm. 5, pp. 1227-1235
-
Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients
Leukemia and Lymphoma, Vol. 63, Núm. 3, pp. 538-550
-
The transcription factor DDIT3 is a potential driver of dyserythropoiesis in myelodysplastic syndromes
Nature Communications, Vol. 13, Núm. 1
2021
-
Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations
British Journal of Haematology, Vol. 194, Núm. 4, pp. 708-717
2020
-
Distinct mutational pattern of myelodysplastic syndromes with and without 5q– treated with lenalidomide
British Journal of Haematology
2014
-
Sequential Third-Party Mesenchymal Stromal Cell Therapy for Refractory Acute Graft-versus-Host Disease
Biology of Blood and Marrow Transplantation, Vol. 20, Núm. 10, pp. 1580-1585
2013
-
Response to lenalidomide in myelodysplastic syndromes with del(5q): Influence of cytogenetics and mutations
British Journal of Haematology, Vol. 162, Núm. 1, pp. 74-86
-
Single nucleotide polymorphism array karyotyping: A diagnostic and prognostic tool in myelodysplastic syndromes with unsuccessful conventional cytogenetic testing
Genes Chromosomes and Cancer, Vol. 52, Núm. 12, pp. 1167-1177